KRAS G12C Peptide

KRAS G12C Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12C oncogenic mutation. KRAS G12C Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12C Peptide can be used for the study of immune responses against KRAS G12C-mutant tumors[1].

1932689-40-1

12352209

IFNAR

Immunology/Inflammation

Cancer-programmed cell death

Cancer

O=C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C)C(N[C@@H](CS)C(NCC(N[C@@H](C(C)C)C(NCC(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C(C)C)N

C38H69N11O11S

888.09

[1]Zheng W, et al. Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development. Oncol Res. 2024 Nov 13;32 (12) :1837-1850.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11357/

Peptides

No Development Reported